目的 探讨参芍胶囊联合盐酸维拉帕米片治疗不稳定型心绞痛的临床疗效。方法 选取2018年2月-2019年2月在四川省骨科医院治疗不稳定型心绞痛的患者92例，根据用药的差别分为对照组（46例）和治疗组（46例）。对照组口服盐酸维拉帕米片，80 mg/次，3次/d；治疗组在对照组的基础上口服参芍胶囊，4粒/次，2次/d。两组患者均治疗4周。观察两组患者临床疗效，同时比较治疗前后两组患者心绞痛发作次数和持续时间，SAQ和GQOLI-74积分，血清C反应蛋白（CRP）、白细胞介素-6（IL-6）、髓过氧化物酶（MPO）、妊娠相关血清蛋白A（PAPP-A）、肌钙蛋白I（CTnI）和脂蛋白磷脂酶A2（Lp-PLA2）水平，以及全血黏度（WBV）、血浆黏度（PV）、纤维蛋白原（FIB）和血小板黏附率（PAR）水平。结果 治疗后，对照组和治疗组临床有效率分别为82.61%和97.83%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者心绞痛发作次数显著降低（P<0.05），心绞痛发作持续时间显著缩短（P<0.05），且治疗组心绞痛发作次数和持续时间显著好于对照组（P<0.05）。治疗后，两组患者SAQ积分、GQOLI-74评分均显著升高（P<0.05），且治疗组QRS和GQOLI-74积分显著高于对照组（P<0.05）。治疗后，两组患者血清CRP、IL-6、MPO、PAPP-A、CTnI、Lp-PLA2水平均明显降低（P<0.05），且治疗组上述血清学指标显著低于对照组（P<0.05）。治疗后，两组患者WBV、PV、FIB、PAR水平均显著降低（P<0.05），且治疗后治疗组WBV、PV、FIB、PAR水平明显低于对照组（P<0.05）。结论 参芍胶囊联合盐酸维拉帕米片治疗不稳定型心绞痛可明显改善患者临床症状，降低血清CRP、IL-6、MPO、PAPP-A、CTnI、Lp-PLA2水平，促进生活质量的改善。

Objective To explore the clinical efficacy of Shenshao Capsules combined with verapamil intreatment of unstable angina pectoris. Methods Patients (92 cases) with unstable angina pectoris in Sichuan Province Orthopaedic Hospital from February 2018 to February 2019 were divided into control (46 cases) and treatment (46 cases) groups based on different treatments. Patients in the control group were po administered with Verapamil Hydrochloride Tablets, 80 mg/time, three times daily. Patients in the treatment group were po administered with Shenshao Capsules on the basis of the control group, 4 grains/time, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the frequency and duration of angina pectoris, the SAQ and GQOLI-74 scores, the serum levels of CRP, IL-6, MPO, PAPP-A, CTnI, and Lp-PLA2, and the WBV, PV, FIB, and PAR levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 82.61% and 97.83%, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency of angina pectoris in two groups was significantly decreased (P<0.05), and the duration of angina pectoris was significantly shorten (P<0.05), and the frequency and duration of angina pectoris in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the SAQ and GQOLI-74 scores in two groups were significantly increased (P<0.05), and these scores in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum levels of CRP, IL-6, MPO, PAPP-A, CTnI, and Lp-PLA2 in two groups were significantly decreased (P<0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the WBV, PV FIB, and PAR levels in two groups were significantly decreased (P<0.05), and these indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Shenshao Capsules combined with verapamil in treatment of unstable angina pectoris can significantly improve the clinical symptoms, reduce the expression of CRP, IL-6, MPO, PAPP-A, CTnI, Lp-PLA2, and improve quality of life.

R972